Tribune News Service
New Delhi, 25 October
The Technical Advisory Group of the World Health Organization will meet on Tuesday to consider the list of emergency uses of India’s indigenous Kovid vaccine, Covaxin.
WHO Chief Scientist Soumya Swaminathan said, “India is working closely with Biotech to complete the WHO dossier.”
Swaminathan said WHO’s goal was to build a comprehensive portfolio of vaccines Approved for emergency use and to expand access to the population everywhere.
Covaxin manufacturer Bharat Biotech is submitting data to WHO on an ongoing basis and has submitted additional information at the request of WHO on 27 September.
WHO experts have reviewed the available information and Bharat Biotech is believed to have addressed most of the queries raised by the world body. Covaxin is developed and produced in India and several countries have expressed interest in the vaccine with India considering export of surplus stock when domestic production increases. WHO has so far included six vaccines in its EUL. These are Pfizer, Johnson & Johnson, SII-AstraZeneca, Moderna, Sinofarm and Sinovac.
Bharat Biotech, the maker of Covaxin, said that as the responsible manufacturer with previous approvals for other vaccines, the firm was working with the WHO to obtain the EUL at the earliest. The approval for Covaxin will make travel easier for Indians vaccinated with the shot and others given that Covaxin has not received approval from national regulators in some countries, including the EU and UK.
All data given: Biotech
Biotech chairman Krishna Ella said that all the necessary documents have been given to consider Covaxin for approval.
$50 million vaccine agreement
An American firm and Hyderabad-based Biological E signed a $50 million deal to expand Covid vaccine manufacturing. previous page
- 14,306 fresh cases
- Total Deaths: 4,54,712
- Active Cases 1,67,695
- 443 deaths in 24 hours